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Abstract 
The ‘Treatment for Adolescents with Depression Study’ (TADS, ClinicalTrials.gov, 
identifier: NCT00006286) was a cornerstone, randomized controlled trial evaluating the 
effectiveness of standard treatment options for major depression in adolescents. Whereas 
previous TADS analyses examined primarily effect modifications of treatment-placebo 
differences by various patient characteristics, less is known about the modification of inter-
treatment differences, and hence, patient characteristics that might guide treatment selection. 
We sought to fill this gap by estimating patient-specific inter-treatment differences as a 
function of patients’ baseline characteristics. We did so by applying the ‘model-based random 
forest’, a recently-introduced machine learning-based method for evaluating effect 
heterogeneity that allows for the estimation of patient-specific treatment effects as a function 
of arbitrary baseline characteristics. Treatment conditions were cognitive-behavioural therapy 
(CBT) alone, fluoxetine (FLX) alone, and the combination of CBT and fluoxetine (COMB). 
All inter-treatment differences (CBT vs. FLX; CBT vs. COMB; FLX vs. COMB) were 
evaluated across 23 potential effect modifiers extracted from previous studies. Overall, FLX 
was superior to CBT, while COMB was superior to both CBT and FLX. Evidence for effect 
heterogeneity was found for the CBT-FLX difference and the FLX-COMB difference, but not 
for the CBT-COMB difference. Baseline depression severity modified the CBT-FLX 
difference; whereas baseline depression severity, patients’ treatment expectations, and 
childhood trauma modified the FLX-COMB difference. All modifications were quantitative 
rather than qualitative, however, meaning that the differences varied only in magnitude, but 
not direction. These findings imply that combining CBT with fluoxetine may be superior to 
either therapy used alone across a broad range of patients. 
 
Keywords 
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Introduction 
The ‘Treatment for Adolescents with Depression Study’ (TADS) was a cornerstone clinical 
trial that evaluated the effectiveness of standard treatment options for major depression in 
adolescents (March et al., 2004; Thapar et al., 2012). These options included treatment with 
the selective serotonin reuptake inhibitor (SSRI) fluoxetine, with cognitive-behavioural 
therapy, and with these two treatments combined. Whereas cognitive-behavioural therapy 
failed to outperform placebo after 12 weeks acute-phase treatment, fluoxetine outperformed 
placebo and the combined therapy outperformed both the placebo and either active therapy 
used alone (March et al., 2004). 
 
Whereas establishing the average effectiveness of a treatment is a necessary step, a major goal 
in the era of personalized and precision medicine is to identify the treatment best-suited for 
each individual (Simon and Perlis, 2010). Indeed, several effect-modification analyses of the 
TADS data have been published, assessing various patient characteristics as potential 
modifiers of the placebo-treatment differences (Curry et al., 2006; Kratochvil et al., 2009; 
Lewis et al., 2010). However, as noted by Simon and Perlis (2010), the hallmark of 
personalized medicine is to be able to choose appropriate treatments for each particular 
patient; that is, to answer the question of whether a patient with characteristic X responds 
better to treatment A than to treatment B. This implies effect modifications of inter-treatment 
differences, which were derived only indirectly and rather informally in previous studies. In 
addition, previous analyses were limited by the drawbacks of conventional effect-
modification analyses, which particularly include testing effect modifiers individually, while 
disregarding all other patient characteristics; spurious effect modifications resulting from 
multiple hypothesis testing and ad-hoc stepwise model building; and the inability to estimate 
patient- versus subgroup-specific treatment effects (Dahabreh et al., 2016; Kent et al., 2010; 
6 
 
Kessler et al., 2017; Moher et al., 2012; Rothwell, 2005; Seibold et al., 2018a; Willke et al., 
2012). 
 
Seibold et al. have recently introduced a statistical approach, called the model-based random 
forest, to tackle effect heterogeneity (Seibold et al., 2018a). This approach blends traditional 
parametric modelling with a machine-learning approach, known as the random forest (hence: 
“model-based random forest”). Considering the perils and critiques associated with traditional 
approaches used in the cited studies, this new approach has a number of advantages. First, it 
allows for deriving a point estimate of the counter-factual treatment effect for each individual 
patient rather than for subgroups of patients. Second, the new approach allows for carrying 
out a global test for the presence of statistically significant heterogeneity within a treatment 
effect across the set of potential effect modifiers. Third, potential effect modifiers are 
considered simultaneously, rather than individually. In this way, complicated effect 
modifications that involve more than one effect modifier can be addressed. Failing to 
incorporate such multidimensional modifications has been found to be a major drawback of 
analyses that only consider one effect modifier at a time (Kent et al., 2010). Fourth, effect 
modification can be dealt with bottom-up, with no need to explicitly define subgroups or 
statistical interaction effects and their functional forms in advance. Finally, the spurious effect 
modification introduced by multiple hypothesis testing and ad-hoc stepwise model building is 
reduced by considering all effect modifier candidates simultaneously and by the set-up of the 
algorithm (Seibold et al., 2018a; Zeileis et al., 2008). 
 
Our aim was to address the afore-mentioned gaps in understanding by analysing for 
heterogeneity in inter-treatment differences for the three active TADS treatment arms, using 
this novel, more comprehensive approach introduced by Seibold et al. In particular, we sought 
to derive point estimates for the counter-factual inter-treatment differences of patients as a 
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function of their baseline characteristics. Our analysis thereby tested for patient characteristics 
that might guide choices between multiple treatments. Failing to conduct such an analysis 
would result in continuing to treat individuals based on estimated average treatment effects, 
be they average effects across all trial subjects, or average effects among specific subject 
subgroups. 
 
 
Methods 
We re-analyzed the data of the acute phase of the TADS trial (ClinicalTrials.gov, 
NCT00006286), which encompassed the first 12 weeks of treatment. TADS is a randomized 
controlled trial (RCT) that was designed to compare the effectiveness of common treatments 
against a pill placebo for the treatment of adolescents with a major depressive disorder 
(MDD). A detailed description of the trial design has already been published elsewhere 
(TADS Team, 2003). TADS was monitored quarterly by the data safety and monitoring board 
of the National Institute of Mental Health (NIMH) of the United States of America (USA). 
The study protocol was approved and monitored by the institutional review boards at each 
study site. Informed written consent was obtained from all patients and at least one of their 
parents. Data were acquired from the NIMH Data Archive (NDA) through a limited-access 
data certificate by the first author. 
 
Study population 
A sample of 439 adolescents who met the criteria for major depressive disorder (MDD) as 
defined in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV, American Psychiatric Association, 1994), were recruited at 13 study sites. Patients 
were 12-17 years old, and 54.4% were female. Roughly 74% were white, 12.5% African 
American, 8.9% Hispanic, and 4.8% other. Roughly 61% reported family incomes of $40,000 
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or higher over the preceding 12 months. Almost 48% had at least one coexisting DMS-IV 
disorder. A comparison of the TADS sample against other clinical and epidemiological 
samples as well as detailed descriptions concerning eligibility criteria, subject recruitment, 
data collection, sample size calculation, and sample characteristics have been published 
elsewhere (March et al., 2004; TADS Team, 2003, 2005). 
 
Interventions 
Detailed descriptions of the intervention arms have been published elsewhere (March et al., 
2004; TADS Team, 2003). The study’s acute phase included a pill placebo (PBO); cognitive-
behavioural therapy (CBT); fluoxetine (FLX); and the combination of CBT and FLX 
(COMB). Eligible patients were randomly assigned to one of the treatment arms, with a 
1:1:1:1 allocation ratio (PBO: n=112; CBT: n=111; FLX: n=109; COMB: n=107), and with 
study site and sex as stratification variables (March et al., 2004). Participants and therapists 
remained blinded to group allocation in the FLX and PBO groups, but were aware that 
patients received active medication in the COMB group and no medication in the CBT group 
(March et al., 2004). 
 
Outcome 
Independent evaluators blinded to treatment arm assignments assessed MDD at baseline and 
at week 12, using the Children’s Depression Rating Scale-Revised (CDRS-R). The CDRS-R 
is a clinician-administered, validated rating scale based on the synthesis of information 
collected by interviewing both the adolescent and a parent (Mayes et al., 2010; Poznanski and 
Mokros, 1995). The raw summary score served as a measure of depression (Curry et al., 2006; 
March et al., 2004). 
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Missing values at the end of the acute phase were replaced by scores predicted by the random 
coefficient regression model used in the original TADS analyses (Curry et al., 2006). This 
imputation method was suggested to provide a less-biased estimate of treatment outcome than 
the last carried forward approach (Curry et al., 2006). Missing values were replaced in sixty-
one (13.9%) of the 439 patients. 
 
Effect modifiers 
We included all the patient characteristics selected by Curry et al. (2006) based on a literature 
review that they conducted prior to their effect modification analysis, with three adaptations. 
First, we replaced ‘comorbidity with disruptive behaviour’ with ‘comorbidity with an 
attention-deficit/hyperactivity disorder (ADHD)’, since ADHD, but not ‘comorbidity with 
disruptive behaviour’ was found to be an effect modifier (Curry et al., 2006; Kratochvil et al., 
2009). Second, since childhood trauma was found to be an effect modifier in a separate TADS 
analysis, it also was included (Lewis et al., 2010). Finally, we also included study site. With 
these adaptations, a final set of 23 potential effect modifiers was included in the analyses 
(Table 1; see references Curry et al., 2006; TADS Team, 2005, for details). Missing values for 
the effect modifiers were handled by the statistical method described below. 
 
Statistical analysis 
Our analysis was an application of the recently-developed ‘model-based random forest’ . 
Details and the mathematical derivation of the method can be found in Seibold et al. (2018a). 
The model-based random forest is an extension of the model-based recursive partitioning 
algorithm outlined by Zeileis and colleagues (Seibold et al., 2016; Zeileis et al., 2008). This 
algorithm was recently shown to be competitive identifying effect modifications (Alemayehu 
et al., 2018). Succinctly, it works as follows: 
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1. Fit a parametric model to the data, consisting of the outcome modelled as a function of 
the intercept and the treatment effect (as would be done in the conventional statistical 
analysis of an RCT) 
2. Test for instability in the model parameters across the potential effect modifiers 
3. If some overall instability is detected, split the data on the effect modifier associated 
with the highest parameter instability; otherwise stop. 
4. Within each resulting data subset (patient subgroup), repeat the algorithm. 
 
Within each node (subgroup) of the tree, a parameter stability test is carried out for each effect 
modifier. If any of the tests is statistically significant, a split is carried out on the effect 
modifier producing the smallest p-value. Across nodes, significance is controlled by closed 
testing, as the tests are nested recursively, meaning that the significance of p-values is only 
interpretable if parameter stability has been rejected for all previous nodes. This algorithm 
set-up assures that only informative effect modifiers are selected, while spurious effect 
modification is dampened, since splits in irrelevant effect modifiers are selected in each node 
only with probability α, and the algorithm stops growing the tree in nodes wherever parameter 
stability cannot be rejected (Seibold et al., 2018a; Zeileis et al., 2008). In addition, the 
algorithm automatically handles missing values amongst the effect modifiers. Once a split has 
been implemented in an effect modifier containing missing values, the observations with 
missing values are randomly assigned to a daughter node following the node distribution. 
During further testing for parameter instability, observations with missing values are ignored. 
 
By applying the algorithm recursively, subgroups with increasingly-homogeneous model 
parameters are derived. Ultimately, rather than having a single global model, several 
subgroup-specific models are estimated, resulting in subgroup-specific treatment effects. 
Crucially, because the effect modifier variables are used to define the subgroups, the model 
11 
 
parameters of the global model can be written as a function of subgroup-defining variables. 
The resulting function of the treatment effect can then be understood as an estimate of the 
counterfactual treatment effect of a patient, with particular values on the effect modifiers 
(Seibold et al., 2018a). 
 
The above-described tree-based algorithm is then extended to a random forest. In a random 
forest, rather than estimating a single tree, an ensemble of trees is estimated (Efron and 
Hastie, 2016). Each model-based tree in the forest is estimated on a randomly-drawn 
subsample of the original data, and each split in the tree is based on a randomly-sampled 
subset of candidate effect modifiers (Efron and Hastie, 2016; Seibold et al., 2018a). Random 
forests have the advantages of allowing for estimating smooth relationship forms, rather than 
being restricted to the step-functions provided by individual trees (Seibold et al., 2018a). The 
treatment effect can, thereby, be estimated as an arbitrary smooth function of the effect 
modifiers. This ability sets this approach apart from other recently-introduced tree-based 
and/or interaction models (Seibold et al., 2018a). 
 
Whereas a conventional random forest would provide information on the similarity of patients 
with respect to the outcome variable, the model-based random forest provides information on 
the similarity of patients with respect to the model parameters and, hence, the treatment effect 
(Seibold et al., 2018a). Thus, the model-based random forest allows for measuring how 
similar patients are, with respect to treatment effect. Based upon this similarity, a personalized 
treatment effect for each patient is estimated by re-calculating the global model, with the 
patients in the data set weighted according to their similarity to the patient under question. 
 
The model-based random forest provides several results (Seibold et al., 2018a). First, since 
patient-specific treatment effects of the sampled patients are estimated, the overall distribution 
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of effects can be examined. A hypothesis test is provided that evaluates whether the patient-
specific effects improve the global model, thereby globally testing for the presence of effect 
heterogeneity across effect modifiers. Second, if evidence of effect heterogeneity is present, 
variable importance measures can be derived that reveal each effect modifier’s contribution in 
the random forest. Third, partial dependence plots can be derived that display patient-specific 
treatment effects as a function of relevant effect modifiers. Finally, the random forest can be 
used to predict the counterfactual treatment effects in future patients. In an RCT with several 
treatment arms, this includes estimating a patient’s treatment effect if he or she had been 
allocated to another treatment arm. 
 
As a global model, we fitted a Gaussian generalized linear model with a log-link and the log 
of baseline depression severity as offset (Seibold et al., 2018a). This amounts to modeling the 
patients’ proportional change from baseline to the end of week 12. A negative treatment 
coefficient means that the expected change from the treatment was more favorable than that 
with the reference condition. Exponentiation of the model intercept produces the expected 
change in the reference condition; whereas exponentiation of the treatment coefficient 
produces the factor by which the change in the treatment condition is higher (or lower) than 
the change in the reference condition. Note that other parametric models could be used as 
global models, depending upon the type of outcome one wishes to study (Seibold et al., 2016; 
Seibold et al., 2018a; Zeileis et al., 2008). 
 
A separate model-based random forest was estimated for each treatment-treatment pair. The 
p-values of the corresponding global effects were adjusted for multiple testing by Holm’s 
procedure (Shaffer, 1995), as were the global tests for the presence of effect heterogeneity. An 
intention-to-treat sample was used in all analyses. Analyses were carried out using R software 
(R Core Team, 2016), based on R-code provided by Seibold et al. (2018a). This code has now 
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been integrated into the newly released and publicly available R-package “model4you” 
(Seibold et al., 2018b). 
 
 
Results 
Overall variability of patient-specific inter-treatment differences 
Table 2 displays the parameter estimates of the global models of all inter-treatment 
differences, summarizes the variability of the estimates, and provides p-values for the tests of 
overall effect heterogeneity. Considering the CBT-FLX difference, the global model indicated 
greater effectiveness of FLX (b = -0.13, 95% CI: -0.22 to -0.05, p = 0.0040). The personalized 
effects ranged from -0.16 to -0.11, with statistical evidence of effect heterogeneity suggested 
by the overall test (p < 0.0001). The distribution of the personalized effects was bimodal 
(Figure 1), again suggesting effect heterogeneity. However, the effects varied only in 
magnitude, not in direction: in the global model, FLX outperformed CBT by a factor of 0.87, 
with factors ranging from 0.86 to 0.89 in the personalized models. 
 
Considering the CBT-COMB difference, COMB was more effective than CBT, as indicated 
by the global model (b = -0.25, 95% CI: -0.33 to -0.17, p < 0.0001). However, there was no 
indication of effect heterogeneity. This was indicated both by the minimal variance in 
personalized effects (-0.25 to -0.23), and by the lack of statistical evidence supporting effect 
heterogeneity from the overall test (p = 0.10, Table 2). 
 
Finally, evidence of effect heterogeneity was identified for the FLX-COMB difference: 
COMB was more effective than FLX (b = -0.11, 95% CI: -0.21 to -0.02, p = 0.023), and the 
personalized effects ranged from -0.13 to -0.10. The overall test for effect heterogeneity 
produced a low p-value (p < 0.0001). The personalized effects also exhibited a bimodal 
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distribution (Figure 1), albeit less pronounced than that found for the CBT-FLX difference. 
Again, the effects varied only in magnitude: in the global model, COMB outperformed FLX 
by a factor of 0.89, with factors ranging from 0.88 to 0.91 in the personalized models. 
 
Importance of patient characteristics 
For the between-treatment differences that exhibited effect heterogeneity, the variable 
importance measures of the patient characteristics are shown in Figure 2. Considering the 
CBT-FLX difference, baseline depression severity was the only patient characteristic with 
large variable importance. In contrast, three patient characteristics were prominent in the 
FLX-COMB difference, again including baseline depression severity, but also the patients’ 
treatment expectations and childhood trauma. 
 
Functional forms of effect modifications 
For patient characteristics deemed important, partial dependence plots were generated to 
uncover the functional forms of the effect modifications. As can be seen in the top-left corner 
of Figure 3, FLX’s superiority over CBT was more pronounced with more severe baseline 
depression. In contrast, COMB’s superiority over FLX was reduced with more severe 
baseline depression (Figure 3, top-right). In addition, COMB’s superiority over FLX was 
stronger in patients who reported higher treatment expectations, whereas childhood trauma 
tended to reduce the difference slightly (Figure 3, bottom-left and –right). These impacts of 
baseline depression severity, treatment expectations, and childhood trauma on COMB’s 
superiority over FLX were also evident when considering the three characteristics 
simultaneously (Figure 4). 
 
Discussion 
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Our aim was to estimate personalized treatment advantages observed in the acute phase of the 
TADS trial as a function of 23 patient baseline characteristics. The most over-riding finding is 
that combined treatment with cognitive-behavioural therapy and fluoxetine was consistently 
superior to either cognitive-behavioural therapy or fluoxetine administered alone, despite 
some heterogeneity in these effects. Thus, rather than supporting the need for specific 
matchings between patients and treatments, as demanded by personalized medicine, the 
personalized treatment advantages that we estimated suggest that the combined treatment 
should be a preferred treatment across a large array of patient characteristics, including 
socioeconomic, demographic and clinical characteristics, and childhood experiences. Previous 
analyses of the TADS data had already uncovered that the combined treatment was the most 
effective in average (March et al., 2004) and had the best benefit-harm profile (March et al., 
2007). Our results additionally suggest that the combined treatment’s superior effectiveness 
might hold for a broad range of patients. 
 
The last claim is bolstered by our analysis’ ability to incorporate 23 potential effect modifiers 
with arbitrary combinations. This was possible due to the model-based random forest’s ability 
to take into account low- as well as high-dimensional effect modification. The superiority of 
the combined treatment should, therefore, generalize across a diverse spectrum of patients, 
characterized by various combinations of these baseline characteristics. Furthermore, TADS 
was designed to be an effectiveness trial (Hollon et al., 2005; March et al., 2004; TADS 
Team, 2005). Accordingly, it featured a relatively large sample that was quite heterogeneous, 
mirroring the heterogeneity of patients seen in actual clinical practice (Hollon et al., 2005; 
March et al., 2004; TADS Team, 2005). As such, its data was believed ripe for effect-
modification analysis (TADS Team, 2003, 2005), and it was suggested that the TADS results 
should be broadly applicable to youths seeking treatment for depression across the USA 
(Hollon et al., 2005; March et al., 2004; TADS Team, 2005). The model-based random 
16 
 
forest’s ability to investigate patient heterogeneity comprehensively is clearly appropriate for 
such a sample. 
 
A second finding was that fluoxetine was superior to cognitive-behavioural therapy, 
consistent with the original effectiveness analysis published by the TADS team (March et al., 
2004). Evidence of effect modification was also present in this treatment advantage, however, 
the personalized treatment advantages varied again only in magnitude, but not in direction. 
The heterogeneity was driven by baseline depression severity: with severer forms of 
depression, the superiority of fluoxetine was more pronounced, whereas for adolescents with 
mild to moderate depression, the difference between the treatments diminished. This seems to 
be in line with findings in depressed adults that SSRI treatment is relatively more effective 
with higher baseline severity of depression (Fournier et al., 2010; Kirsch et al., 2008), 
although this finding has been disputed (Fountoulakis et al., 2013; Rabinowitz et al., 2016). 
Future research should further clarify this issue in depressed adolescents. 
 
Notwithstanding the statistical comprehensiveness of our analysis, it is surprising that we did 
not find evidence that allowed for an unequivocal personalization of treatments. There are 
several potential explanations. First, the patient characteristics included in our analyses did 
not encompass a variety of other potential effect modifiers (Iosifescu, 2011; Leuchter et al., 
2010; McGrath et al., 2013; Strawbridge et al., 2017; Uhr et al., 2008), in particular a variety 
of potential biomarkers (Harmer et al., 2011; Leuchter et al., 2016; Porcelli et al., 2011). 
Eventually, one or several of these variables would produce effect modifications that allow 
for personalizing treatment decisions (e.g. Uhr et al., 2008). Future studies should close this 
gap especially concerning the role of biological measures. 
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Second, commonly-used depression rating scales have been criticized for not being 
psychometrically valid (Bech, 2010; Fried and Nesse, 2015; Fried et al., 2016) and this issue 
has been raised with the CDRS-R (Isa et al., 2014). If the outcome measure used is unreliable, 
true effect heterogeneity might be clouded by measurement error, especially in case of smaller 
effect modifications. Note, however, that this is unlikely to explain all of our results, since our 
analysis did reveal some effect heterogeneity. 
 
Third, RCTs, including TADS, are usually powered to detect average treatment effects. As a 
result, sample sizes within subgroups, as implied by effect modifiers, often become small and 
imbalanced (Rothwell, 2005; Willke et al., 2012). Several patient characteristics in our 
analysis might have been affected by this problem, such as dysthymia, ADHD, and some 
forms of childhood trauma (see table 1). For example, only 46 TADS patients had dysthymia, 
so that the number of dysthymic patients in the four groups ranged from a low of six to a high 
of 17. Any effect-modification analysis is limited by these low numbers, making the results 
less reliable for these characteristics. Note that this problem did not universally apply to the 
patient characteristics included in our analysis (table 1), however. 
 
Fourth, it might be necessary to take harms additionally into account for arriving at 
personalized treatment decisions. As already mentioned above, although we found a 
consistent treatment advantage of fluoxetine over cognitive-behavioral therapy, there was 
heterogeneity in this advantage. In fact, the personalized advantages showed a bi-modal 
distribution with the bi-modality being driven by baseline depression severity: with less 
severe depression the advantage diminished. If fluoxetine’s superiority diminishes for less 
severely depressed adolescents, cognitive-behavioural therapy might be a better treatment 
choice for these patients if the (personalized) risk of harm associated with fluoxetine is 
additionally taken into account, because SSRI treatment was found to confer some danger for 
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adolescents especially regarding suicidality (Sharma et al., 2016). This resonates indeed with 
the conclusion drawn by Cipriani et al (2016) who - based on their network meta-analysis - 
stated that fluoxetine should only be considered for adolescents with moderate-severe 
depression. Future studies should therefore examine more closely the trade-off between 
personalized treatment advantage and personalized harm. Note, however, that the combined 
treatment of fluoxetine and cognitive-behavioral therapy was found to have the best benefit-
harm account in the TADS sample (March et al., 2007), so this line of reasoning seems less 
important for the combined therapy, at least in the TADS sample. 
 
Fifth, the previous literature has produced mixed results regarding the effectiveness of both 
combined treatments (Brent et al., 2008; Cox et al., 2014; Dubicka et al., 2010; Goodyer et 
al., 2008; Hetrick et al., 2011; Ma et al., 2014; Melvin et al., 2006) and SSRIs (Bridge et al., 
2007; Cheung et al., 2008; Cipriani et al., 2016; Cox et al., 2012; Emslie et al., 2004; Emslie 
et al., 2008; Findling et al., 2013; Hetrick et al., 2012; Le Noury et al., 2015, 2016; Masi et 
al., 2010; Usala et al., 2008; Wagner et al., 2003; Wagner et al., 2006; Wagner et al., 2004; 
Whittington et al., 2004) in adolescents; though the drug that has received the most-consistent 
empirical support has been fluoxetine (Cipriani et al., 2016; Masi et al., 2010; Usala et al., 
2008). In addition, the limited effectiveness of cognitive-behavioural therapy in TADS was 
unanticipated (Harrington et al., 1998; Hollon et al., 2005; Klein et al., 2007; Masi et al., 
2010; Reinecke et al., 1998; Weersing and Brent, 2006; Weersing et al., 2017; Weersing et 
al., 2009; Weisz et al., 2006). With such mixed results, two scenarios are plausible. On one 
hand, this situation might  be caused by the presence of strong effect modifiers: if a treatment 
has a positive effect in some patients, but no or a negative effect in others, the average effect 
is small or zero. On the other hand, the treatments might be limited in what they can achieve 
and effect modification may be limited accordingly. 
 
19 
 
Unfortunately, whereas our results seem more in line with the second scenario, the broader 
state of affairs is less clear. Existing studies are difficult to compare, since they refer to a 
variety of comparisons, including those comparing active treatment and placebo (Cheung et 
al., 2010; Curry et al., 2006; Emslie et al., 2012), comparisons between different forms of 
psychotherapy (Birmaher et al., 2000; Brent et al., 1998), comparisons of psychotherapy 
against inactive control conditions (Harrington et al., 1998), and comparisons of combined 
treatments with medication augmentation and alterations, in adolescents with SSRI-resistant 
depression (Asarnow et al., 2009). In addition, the studies were limited by the drawbacks of 
conventional effect-modification analyses. Not surprisingly, these studies failed to reveal 
patient characteristics that show up consistently as effect modifiers. On the other hand, the 
shortage of robust effect modifiers in previously-published literature agrees with our findings 
that only three out of the 23 patient characteristics we assessed acted as an effect modifier, 
and that the effect heterogeneity induced by these modifiers was limited. 
 
Overall, then, we found evidence for the superiority of the combination of cognitive-
behaviour therapy and fluoxetine in the TADS sample. Due to the issues discussed above, our 
results should nevertheless be considered exploratory. Future studies must replicate and 
validate our findings in even larger trials, or in data sets combining several trials, and include 
important additional patient characteristics. 
 
Limitations 
Limitations of the TADS trial have been noted by others (Curry et al., 2006; March et al., 
2004) and other issues were addressed above. Additional misgivings should be mentioned. 
First, analyses were done separately for every treatment-treatment pair. This might have 
introduced additional variability. Technically, it is possible to analyze a global model that 
contains all treatment conditions simultaneously (Seibold et al., 2018a). However, the results 
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of such an analysis would not be straightforward to interpret. Second, other statistical 
approaches exist that allow for a more comprehensive assessment of effect modification than 
the conventional approaches based on stratification and parametric interaction effects. These 
include, for example, recently-proposed machine-learning approaches (Chekroud et al., 2016; 
Jakubovski and Bloch, 2014; Kelly et al., 2015) and the multivariable risk prediction 
approach (Kent et al., 2010; Perlis, 2013; Varadhan et al., 2013). A systematic comparison of 
these methods – including the model-based random forest – has not been carried out yet, 
especially concerning the pivotal question of whether these approaches would lead to 
divergent treatment decisions. Future studies should address this issue. Finally, our analysis 
was a post-hoc analysis of data collected during a trial that was not originally designed for our 
intended analysis. 
 
Conclusions 
In the TADS sample, the combination of cognitive-behaviour therapy and fluoxetine was 
superior to either therapy used alone across a broad range of patient characteristics. Future 
studies may benefit from applying the model-based random forest method to analyse effect 
heterogeneity.  
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Table 1 Overview of patient characteristics examined as effect modifiers. 
Categorical patient characteristic Categories n % - - Scale 
Gender female 239 54.4   binary  
male 200 45.6    
Race majority (white) 324 73.8   binary 
 minority 115 26.2    
Family income ≥ 75000 100 25.4   binary 
 < 75000 294 74.6    
Referral source no advertisement 193 44   binary 
 advertisement 246 56    
Dysthymia no 392 89.5   binary 
 yes 46 10.5    
Anxiety disorder no 318 72.6   binary 
 yes 120 27.4    
ADHD no 377 85.9   binary 
 yes 62 14.1    
Childhood trauma NT 213 48.5   categorical 
 TNA 148 33.7    
 CSA 38 8.7    
 PA 40 9.1    
Study site 1 20 4.6   categorical 
 2 33 7.5    
 3 33 7.5    
 4 20 4.6    
 5 64 14.6    
 6 41 9.3    
 7 50 11.4    
 8 19 4.3    
 9 21 4.8    
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 10 8 1.8    
 11 34 7.7    
 12 10 2.3    
 13 86 19.6    
Numeric patient characteristic Mean SD Median IQR Range  
Age 14.6 1.5 15 13-16 12-17 years 
Verbal intelligence 10.7 2.4 11 9-12 6-19 vocabulary subtest of the WISC-III scaled score 
Current episode duration 72.2 83.1 40 20-102 3-572 weeks 
Baseline depression severity 4.8 0.8 5 4-5 3-7 CGI-S score 
Functional impairment 49.6 7.5 50 45-55 32-80 CGAS score 
Suicidal ideation 23.7 21.8 16 7-37 0-89 SIQ-Jr score 
Melancholic features 1.3 0.9 1 1-2 0-5 count 
Number comorbid diagnoses 0.9 1.1 1 0-1 0-5 count 
Caregiver depression 12.5 9.7 10 5-18.2 0-43 BDI-II score 
Conflict with caregiver 8.4 4.8 8 5-12 0-21 CBQ score 
Hopelessness 9.9 5.6 10 5.5-14.5 0-20 BHS score 
Cognitive distortions 62.6 20.6 63 46-76 24-120 CNCEQ score 
Treatment expectations parents 1.8 0.9 2 1-2 -3-3 7-point Likert scale 
Treatment expectations adolescents 1.6 1 2 1-2 -3-3 7-point Likert scale 
SD: Standard deviation; IQR: Inter-quartile range; ADHD: Attention-Deficit/Hyperactivity Disorder; NT: no trauma; TNA: trauma but no abuse; 
CSA: childhood sexual abuse or both sexual and physical abuse; PA: physical abuse and/or victim of a violent crime; WISC-III: Wechsler 
intelligence scale for children 3. Edition; CGI-S: Clinical Global Impressions-Severity scale; CGAS: Children’s Global Assessment Scale; SIQ-Jr: 
Suicidal Ideation Questionnaire Grades 7–9; BDI-II: Beck Depression Inventory II; CBQ: Conflict Behaviour Questionnaire; BHS: Beck 
Hopelessness Scale; CNCEQ: Children`s Negative Cognitive Errors Questionnaire. 
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Table 2. Global model and variability of patient-specific effects. 
 Global 
model 
   Variability of model coefficients across patient 
characteristics 
Test for overall effect 
heterogeneity a 
Treatment-treatment difference Coefficient 95% CI 
low 
95% CI 
high 
p-value Median IQR low IQR high Min Max p-value 
1 Intercept -0.37 -0.42 -0.31 < 0.0001 -0.36 -0.37 -0.36 -0.37 -0.36  
 CBT vs. FLX -0.13 -0.22 -0.05 0.0040 -0.15 -0.15 -0.12 -0.16 -0.11 < 0.0001 
2 Intercept -0.37 -0.42 -0.32 < 0.0001 -0.37 -0.37 -0.37 -0.37 -0.36  
 CBT vs. COMB -0.25 -0.33 -0.17 < 0.0001 -0.24 -0.25 -0.24 -0.25 -0.23 0.10 
3 Intercept -0.50 -0.57 -0.44 < 0.0001 -0.51 -0.51 -0.48 -0.52 -0.48  
 FLX vs. COMB -0.11 -0.21 -0.02 0.023 -0.11 -0.12 -0.10 -0.13 -0.10 < 0.0001 
CBT: Cognitive-behavioural therapy. FLX: Fluoxetine. COMB: Combination of CBT and FLX. CI: Confidence interval. IQR: Interquartile range; 
Min: Minimum; Max: Maximum. 
a Tests whether patient-specific treatment-treatment-differences result in an improvement of the global model. 
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Figure 1. Patient-specific inter-treatment-differences 
 
CBT: Cognitive-behavioural therapy; FLX: Fluoxetine; COMB: Combination of CBT and FLX; β: regression coefficient (inter-treatment-
difference) 
The figure shows kernel density plots of patient-specific inter-treatment-differences as estimated by model-based random forests, along with the 
global inter-treatment-difference (“Global model”). The left plot shows patient-specific differences between CBT and FLX, whereas the right plot 
shows the patient-specific differences between FLX and COMB.  
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Figure 2. Variable importance of patient characteristics examined as effect modifiers. 
 
CBT: Cognitive-behavioural therapy; FLX: Fluoxetine; COMB: Combination of CBT and FLX; ADHD: Attention-deficit/hyperactivity disorder. 
The figure shows the variable importance of patient characteristics that might act as effect modifiers of inter-treatment-differences, as estimated by 
model-based random forests. Patient characteristics with a high variable importance are likely to be effect modifiers. The left plot shows patient 
characteristics that modify the inter-treatment-difference of CBT and FLX, whereas the right plot is for the inter-treatment-difference of FLX and 
COMB.   
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Figure 3. Patient-specific inter-treatment differences as a function of effect modifiers 
 
CBT: Cognitive-behavioural therapy; FLX: Fluoxetine; COMB: Combination of CBT and FLX; β: regression coefficient (inter-treatment-
difference); NA: Not available (missing values); NT: no trauma; CSA: childhood sexual abuse or both sexual and physical abuse; PA: physical 
abuse and/or victim of a violent crime; TNA: trauma but no abuse. 
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The figure shows partial dependence plots displaying patient-specific inter-treatment differences as a function of effect modifiers. The plot in the 
top left corner shows the inter-treatment difference of CBT and FLX as a function of baseline depression severity, whereas the remaining plots show 
the inter-treatment difference of FLX and COMB as a function of baseline depression severity, adolescents’ treatment expectations, and childhood 
trauma, respectively. Baseline depression severity was measured via the Clinical Global Impressions-Severity scale (CGI-S): 3 = “mildly ill“; 4 = 
“moderately ill“; 5 = “markedly ill”; 6 = “severely ill”; 7 = “among the most extremely ill patients”. 
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Figure 4. Simultaneous impact of baseline depression severity, treatment expectations, and childhood trauma on the superiority of the combination 
of fluoxetine with cognitive-behavioural therapy over fluoxetine alone 
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FLX: Fluoxetine; COMB: Combination of cognitive-behavioural therapy and FLX; β: regression coefficient (inter-treatment-difference); NA: Not 
available (missing values); NT: no trauma; CSA: childhood sexual abuse or both sexual and physical abuse; PA: physical abuse and/or victim of a 
violent crime; TNA: trauma but no abuse. 
The figure shows the impact of baseline depression severity, treatment expectations, and childhood trauma on COMB’s superiority over FLX. The 
figure is divided into four subfigures, each one portraying one trauma category (NT, CSA, PA, TNA). In each subfigure, the personalized treatment-
differences are plotted against baseline depression severity and color-coded for treatment expectations. Note that the subfigures were jittered to 
reduce over-plotting: within each level of baseline depression severity, the corresponding points would truly lie on a single line (see Figure 3, top-
right plot) rather than being scattered around the severity level. Baseline depression severity was measured via the Clinical Global Impressions-
Severity scale (CGI-S): 3 = “mildly ill“; 4 = “moderately ill“; 5 = “markedly ill”; 6 = “severely ill”; 7 = “among the most extremely ill patients”. 
 
